Loading
Life sciences · Journal article
Endocrinology Insights · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction: With one of the highest prevalence rates in Europe, diabetes mellitus (DM) poses a significant public health and economic challenge in Portugal. However, current data on its prevalence and glucose monitoring practices remain scarce. This study aimed to establish expert consensus on the current DM epidemiology landscape in Portugal, evaluate current glucose test strips and continuous glucose monitoring (CGM) sensor utilisation patterns, and gather insights about the tools using AI for DM management. Methods: A modified Delphi methodology was employed, involving two rounds of expert consultation with five diabetes specialists across Portugal in 2025. The panel assessed structured questionnaires covering DM prevalence, CGM sensor and test strip utilisation patterns, and insights about silico studies for AI-mediated DM management. Anonymised responses were discussed in a moderated virtual session to reach consensus. Results: Continuous glucose monitoring adoption among individuals with type 1 DM (T1DM) was estimated at 56% with projections indicating continued growth. Uptake was lower for type 2 DM but could rise with policy support, mainly among patients on insulin. In silico models were recognized as valid evidence sources for evaluating AI-based DM interventions contingent on data quality and contextual relevance. Conclusion: Study highlights rising DM prevalence in Portugal, especially in public healthcare, with rising CGM adoption rates, particularly for T1DM. Experts emphasised the need for improvement in broader CGM access and data recording, to improve AI-enabled DM treatment outcomes.